Anthracycline Cardiotoxicity
Anthracycline Cardiotoxicity - Related Videos
04:47
Zebrafish Cardiomyopathy Model: Drug-Induced Cardiotoxicity
0 Views •
2023
This video describes the technique of creating a zebrafish cardiomyopathy model with minimal variations among experimental groups and in the sample, we create zebrafish cardiomyopathy model using the drug doxorubicin.
11:00
Using Chicken Embryo as a Powerful Tool in Assessment of Developmental Cardiotoxicities
0 Views •
Cited by 2 •
2021
Chicken embryos, as a classical developmental model, are used in our lab to assess developmental cardiotoxicities following exposure to various environmental contaminants. Exposure methods and morphological/functional assessment methods established are described in this manuscript.
14:03
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
0 Views •
Cited by 6 •
2023
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer an alternative to using animals for preclinical cardiotoxicity screening. A limitation to the widespread adoption of hiPSC-CMs in preclinical toxicity screening is the immature, fetal-like phenotype of the cells. Presented here are protocols for robust and rapid maturation of hiPSC-CMs.
07:56
Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
0 Views •
Cited by 18 •
2010
For development of RNA interference (RNAi)-based therapies, a novel strategy was developed, transkingdom RNAi (tkRNAi). This technology uses non-pathogenic bacteria to produce and deliver therapeutic short hairpin RNA (shRNA) into target cells. Here, tkRNAi was successfully applied for reversal of classical ABCB1-mediated multidrug resistance (MDR) of cancer cells.
FAQs
Anthracycline exposure can damage cardiomyocytes through oxidative stress, impair mitochondrial function, and disrupt topoisomerase IIβ. These cellular disturbances help explain how treatment-related injury can progress to reduced left ventricular function. Connecting these mechanisms with clinical cardiac assessment helps medicine recognize potential toxicity while supporting decisions about how to preserve the benefits of cancer treatment.
Risk is influenced by cumulative anthracycline dose and patient factors, so toxicity cannot be interpreted from a single exposure in isolation. Reviewing treatment history provides dose-related context, while assessing patient factors helps identify individuals who may require closer cardiac evaluation. This risk-based perspective supports dose management and follow-up without assuming that every patient has the same vulnerability.
Mechanistic knowledge clarifies why anthracycline therapy can create a cardiovascular complication that limits cancer treatment. Recognizing oxidative stress, mitochondrial dysfunction, and topoisomerase IIβ disruption supports the development and use of cardioprotective strategies. It also helps clinicians balance cardiac safety with the anticancer purpose of treatment, rather than considering cardiac injury separately from cancer-care decisions.
Evaluation combines cardiac imaging, biomarker assessment, and review of the patient’s anthracycline treatment history. Imaging helps assess cardiac function, biomarkers provide additional information about possible cardiac injury, and treatment-history review places findings in the context of cumulative exposure. Together, these approaches help identify patients at risk and detect clinically important changes during or after cancer therapy.
Monitoring can identify changes in cardiac function, including evidence of left ventricular dysfunction that may signal progression toward heart failure. Detecting these changes provides clinically relevant information about how the heart is responding to prior or ongoing treatment. The findings can then inform cardiac follow-up, dose management, or consideration of cardioprotective strategies while cancer care continues.
Anthracycline-related cardiac effects can remain relevant beyond the period of active cancer treatment, making long-term monitoring important for survivors. Continued evaluation can help detect changes in cardiac function and identify emerging left ventricular dysfunction or heart failure. This survivorship focus extends cardiovascular care beyond treatment decisions and supports recognition of late clinical consequences after anthracycline exposure.